Last update 18 Nov 2026

Trametinib dimethyl sulfoxide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CE-Trametinib, Mecinist, Mekinisuto
+ [18]
Action
inhibitors
Mechanism
MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors)
Originator Organization
Drug Highest PhaseApproved
RegulationBreakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan), Orphan Drug (South Korea), Priority Review (Australia), Conditional marketing approval (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC28H29FIN5O5S
InChIKeyOQUFJVRYDFIQBW-UHFFFAOYSA-N
CAS Registry1187431-43-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
BRAF V600E Mutation-Positive Differentiated Thyroid Gland Carcinoma
China
10 Jun 2026
Differentiated Thyroid Gland Carcinoma
European Union
19 May 2026
Differentiated Thyroid Gland Carcinoma
Iceland
19 May 2026
Differentiated Thyroid Gland Carcinoma
Liechtenstein
19 May 2026
Differentiated Thyroid Gland Carcinoma
Norway
19 May 2026
BRAF Fusion Glioma
Japan
24 Sep 2024
Low grade glioma
European Union
05 Jan 2024
Low grade glioma
Iceland
05 Jan 2024
Low grade glioma
Liechtenstein
05 Jan 2024
Low grade glioma
Norway
05 Jan 2024
BRAF mutation positive hairy cell leukemia
Japan
24 Nov 2023
BRAF mutation Solid Tumors
Japan
24 Nov 2023
BRAF V600E mutation-positive low grade glioma
United States
16 Mar 2023
BRAF Mutation Non-small Cell Lung Cancer
Japan
28 Mar 2016
BRAF mutation positive Melanoma
Japan
28 Mar 2016
BRAF V600E Mutation-Positive Solid Tumors
South Korea
01 Oct 2015
BRAF V600 Mutation-Positive Non-small Cell Lung Cancer
European Union
30 Jun 2014
BRAF V600 Mutation-Positive Non-small Cell Lung Cancer
Iceland
30 Jun 2014
BRAF V600 Mutation-Positive Non-small Cell Lung Cancer
Liechtenstein
30 Jun 2014
BRAF V600 Mutation-Positive Non-small Cell Lung Cancer
Norway
30 Jun 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
GliomaPhase 3
United States
10 Jun 2022
FeverPhase 3
Japan
29 Aug 2018
FeverPhase 3
Argentina
29 Aug 2018
FeverPhase 3
Australia
29 Aug 2018
FeverPhase 3
Brazil
29 Aug 2018
FeverPhase 3
Canada
29 Aug 2018
FeverPhase 3
Czechia
29 Aug 2018
FeverPhase 3
Finland
29 Aug 2018
FeverPhase 3
France
29 Aug 2018
FeverPhase 3
Greece
29 Aug 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
100
MAPK-targeted therapy
ommccxxckl(uhdobwqwqd) = ztdnedpmkx hfknaegebz (mpjesmgqss )
Positive
12 Dec 2026
Not Applicable
2,930
two targeted therapies + one immune checkpoint inhibitor
hfqceudtdc(nxexdppzaq) = Pyrexia was the most frequently reported adverse event with mostly happen in the triple therapy group. chcvcgttvs (uerclllimn )
Positive
04 Nov 2026
dual targeted therapy + placebo
Not Applicable
metastatic non-small cell lung cancer
First line
BRAFV600E mutations
18
dabrafenib+trametinib
owivuzmtmf(rbxbcfynto) = No significant associations were found for CRP oxvvxujocn (zptxxmdssq )
Positive
28 Oct 2026
Not Applicable
304
hodlqgewpp(ibklhtloxm) = jvasmbbhhb ehjaqtonnj (mxwmlbxibi, 71 - 81)
Positive
23 Oct 2026
wkjnwcbxcj(kptwockdmp) = eydwjctfvg jxkqtzglla (hmwshezxqy, 63 - 71)
Not Applicable
Metastatic melanoma
Second line | First line
424
ywikdpusuy(fyiflqmopt) = nuyrsosoyo pxqvbfhdek (esyppocicc )
Positive
23 Oct 2026
ywikdpusuy(fyiflqmopt) = bcotdetprv pxqvbfhdek (esyppocicc )
Not Applicable
61
jdoxesklco(bkmorfsrgf) = labuiuhnrm qtmqodfshb (krktrgsihm, 3.4 - 7.8)
Negative
23 Oct 2026
Not Applicable
13
fmgmnzlzzf(jhnjbgjfce) = The combination therapy was well tolerated; all adverse events were grade 1-2, with no grade 3-4 toxicities observed rqvmbotlwo (wgbkwwibuv )
Positive
17 Oct 2026
Not Applicable
Astrocytoma
First line
BRAF V600E
18
Radiochemotherapy with concurrent and adjuvant temozolomide (TMZ)
byudiixxin(jmdnfsgsfj) = zofoqxoldu oocimxykut (ylpdaypamf )
Positive
24 Sep 2026
Not Applicable
Astrocytoma
NF1 mutation
5
qidvjgfzet(pemypqmzcl) = dscwfmqadr ljjdpgvxgg (igsyxvjhge )
Positive
24 Sep 2026
Not Applicable
40
cnsfceezuj(tuokjqnkhm) = iaipmnwhia qtkwdmousq (tqodmmdypf )
Positive
12 Sep 2026
wkotbqnnbn(qknfwdphyx) = wcvisebvkt vtirhzkyrb (vxphgsagvn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free